All companies
LivaNova PLC logo

What smart money is saying about LivaNova PLCUnited Kingdom flag

LIVN · Healthcare · Medical - Devices · Market cap $4.40B

2 funds in our archive have pitched LivaNova PLC — most recently Artisan Partners Non-U.S. Small-Mid Growth Strategy in June 2026.

Company profile

LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.

Get an email when a fund writes about it

Summarize with Warren AI
1
Reported positions
0
Bought
0
Sold
2
Letters

Position history

Between Q4 2025 and Q2 2026, 1 fund letter reported a position in LivaNova PLC, with no move described.

Fund letters reporting a position in LivaNova PLC, by quarter
QuarterLettersBoughtSoldTheses
Q2 20261001
Q4 20250001

Fund activity · 1 position

  • HoldsArtisan Partners Non-U.S. Small-Mid Growth Strategy
    June 2026
    Our top contributors for the quarter were Rohm, LivaNova and Glanbia.
    Read the letterLivaNova PLC

Fund coverage · 2 theses

  • Artisan Partners Non-U.S. Small-Mid Growth Strategy
    June 2026

    LivaNova combines dominant cardiopulmonary market share, a growing neuromodulation business and an approved sleep-apnea pipeline with long growth runway.

    Read the full thesis
  • Artisan Non-U.S. Small-Mid Growth Strategy
    December 2025

    LivaNova PLC is a medtech leader with dominant cardiopulmonary share, improving execution under new leadership, and meaningful neuromodulation pipeline optionality.

    Read the full thesis

Read every full thesis on LivaNova PLC

Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans
Share this ledger